Wells Fargo’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $772K | Sell |
35,725
-63,593
| -64% | -$1.37M | ﹤0.01% | 3895 |
|
|
2025
Q4 | $2.37M | Buy |
99,318
+31,002
| +45% | +$633K | ﹤0.01% | 3307 |
|
|
2025
Q3 | $929K | Buy |
68,316
+18,522
| +37% | +$193K | ﹤0.01% | 3871 |
|
|
2025
Q2 | $405K | Buy |
49,794
+10,603
| +27% | +$90.6K | ﹤0.01% | 4295 |
|
|
2025
Q1 | $308K | Buy |
39,191
+573
| +1% | +$6.64K | ﹤0.01% | 4408 |
|
|
2024
Q4 | $575K | Buy |
38,618
+19,865
| +106% | +$324K | ﹤0.01% | 4078 |
|
|
2024
Q3 | $287K | Buy |
18,753
+139
| +0.7% | +$2.19K | ﹤0.01% | 4343 |
|
|
2024
Q2 | $283K | Sell |
18,614
-755
| -4% | -$12.2K | ﹤0.01% | 4278 |
|
|
2024
Q1 | $366K | Buy |
19,369
+2,931
| +18% | +$50.7K | ﹤0.01% | 4091 |
|
|
2023
Q4 | $314K | Sell |
16,438
-50,022
| -75% | -$799K | ﹤0.01% | 4180 |
|
|
2023
Q3 | $1.19M | Sell |
66,460
-9,287
| -12% | -$187K | ﹤0.01% | 3203 |
|
|
2023
Q2 | $1.54M | Sell |
75,747
-5,672
| -7% | -$108K | ﹤0.01% | 3122 |
|
|
2023
Q1 | $1.49M | Buy |
81,419
+78,312
| +2,521% | +$1.5M | ﹤0.01% | 3109 |
|
|
2022
Q4 | $64.3K | Sell |
3,107
-2,795
| -47% | -$76.9K | ﹤0.01% | 4750 |
|
|
2022
Q3 | $155K | Buy |
5,902
+154
| +3% | +$4.07K | ﹤0.01% | 4370 |
|
|
2022
Q2 | $145K | Sell |
5,748
-23,742
| -81% | -$581K | ﹤0.01% | 4448 |
|
|
2022
Q1 | $930K | Sell |
29,490
-13,687
| -32% | -$459K | ﹤0.01% | 3958 |
|
|
2021
Q4 | $1.75M | Buy |
43,177
+5,229
| +14% | +$203K | ﹤0.01% | 3635 |
|
|
2021
Q3 | $1.32M | Buy |
37,948
+6,515
| +21% | +$203K | ﹤0.01% | 4007 |
|
|
2021
Q2 | $863K | Sell |
31,433
-19,598
| -38% | -$560K | ﹤0.01% | 4304 |
|
|
2021
Q1 | $1.43M | Sell |
51,031
-57,254
| -53% | -$1.99M | ﹤0.01% | 3989 |
|
|
2020
Q4 | $2.81M | Buy |
108,285
+18,287
| +20% | +$443K | ﹤0.01% | 3244 |
|
|
2020
Q3 | $1.54M | Buy |
89,998
+1,843
| +2% | +$41.2K | ﹤0.01% | 3520 |
|
|
2020
Q2 | $2.18M | Buy |
88,155
+68,606
| +351% | +$1.85M | ﹤0.01% | 3204 |
|
|
2020
Q1 | $271K | Sell |
19,549
-1,416
| -7% | -$17.6K | ﹤0.01% | 4478 |
|
|
2019
Q4 | $212K | Buy |
20,965
+27
| +0.1% | +$227 | ﹤0.01% | 4920 |
|
|
2019
Q3 | $191K | Sell |
20,938
-13,179
| -39% | -$106K | ﹤0.01% | 4987 |
|
|
2019
Q2 | $272K | Sell |
34,117
-13,408
| -28% | -$134K | ﹤0.01% | 4793 |
|
|
2019
Q1 | $593K | Sell |
47,525
-2,800
| -6% | -$30.4K | ﹤0.01% | 4226 |
|
|
2018
Q4 | $542K | Buy |
50,325
+40,165
| +395% | +$469K | ﹤0.01% | 4280 |
|
|
2018
Q3 | $142K | Buy |
10,160
+350
| +4% | +$4.46K | ﹤0.01% | 5193 |
|
|
2018
Q2 | $120K | Sell |
9,810
-200
| -2% | -$3.14K | ﹤0.01% | 5301 |
|
|
2018
Q1 | $155K | Buy |
+10,010
| New | +$167K | ﹤0.01% | 5110 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Wells Fargo's RCUS Position: Q1 2026 in Review
Wells Fargo reduced its Arcus Biosciences (RCUS) stake by 64% in Q1 2026, selling an estimated $1.37M and leaving 35,725 shares worth $772K. The position accounts for ﹤0.01% of the portfolio, ranked #3895.
Wells Fargo first reported a position in RCUS in Q1 2018 and has held it in 33 quarters since. The position peaked at $2.81M in Q4 2020. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Wells Fargo held 35,725 shares of Arcus Biosciences worth $772K as of Q1 2026.
- Wells Fargo sold 63,593 Arcus Biosciences shares in Q1 2026, an estimated $1.37M.
- Arcus Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3895 holding.
- Wells Fargo first reported a position in Arcus Biosciences in Q1 2018 and has held it in 33 quarters since.
- Wells Fargo's Arcus Biosciences position peaked at $2.81M in Q4 2020.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.